Hepatitis A News and Research

RSS

Hepatitis A (formerly known as ''infectious hepatitis'') is an acute infectious disease of the liver caused by the hepatitis A virus (HAV), which is most commonly transmitted by the fecal-oral route via contaminated food or drinking water.

Conquering cancer: A global effort

Despite the recent good news that cancer incidence and death rates for men and women in the United States continue to decline, cancer is projected to become the leading cause of death worldwide in the year 2010, and low- and middle-income countries will feel the impact of higher cancer incidence and death rates more sharply than industrialized countries.

10 Dec 2008

Hep C treatment pegylated interferon reduces the virus but liver damage continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

10 Dec 2008

Vaccine against malaria could be ready in 5 years

Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome.

9 Dec 2008

Potential new therapy for hepatitis C treatment

Combination therapies similar to those used for HIV patients may be the best way of treating hepatitis C virus (HCV), say researchers from the University of Leeds.

8 Dec 2008

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Hep C treatment peginterferon reduces the virus but liver damage continues

5 Dec 2008

Interferon as long-term treatment for hepatitis C not effective

Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.

5 Dec 2008

Low-dose peginterferon used for hepatitis C doesn't work

An NIH funded multi-center clinical trial found no benefit from "maintenance therapy," low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment.

3 Dec 2008

Scientists discover how ovarian tumors evade immune system

Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked.

1 Dec 2008

Etanercept found to be ineffective in treating alcoholic hepatitis

A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.

1 Dec 2008

Childhood vaccines cause financial burden to many health care providers

The costs that health care providers are charged and reimbursed for childhood vaccines vary widely, and the high cost of some immunizations is leading to significant financial strain for some physicians, according to a pair of new studies from the University of Michigan Health System.

1 Dec 2008

Antibiotics causing most drug-induced liver injury

Antibiotics are the single largest class of agents that cause idiosyncratic drug-induced liver injury (DILI), reports a new study in Gastroenterology, an official journal of the American Gastroenterological Association (AGA) Institute.

1 Dec 2008

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor.

1 Dec 2008

Liver disease tackled with dedicated unit at Imperial College London

Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.

1 Dec 2008

Research identifies cell receptor as target for anti-inflammatory immune response

Cell reception. By comparing normal mice (left) with mice that are genetically engineered to lack certain receptors in their spleen (right), scientists have shown SIGNR1 receptors (blue) are required to facilitate an anti-inflammatory action.

28 Nov 2008

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies

Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

Common cold virus originated in birds

A virus that causes cold-like symptoms in humans originated in birds and may have crossed the species barrier around 200 years ago, according to an article published in the December issue of the Journal of General Virology.

20 Nov 2008